217 related articles for article (PubMed ID: 34540765)
21. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
22. An updated review on activated PI3 kinase delta syndrome (APDS).
Singh A; Joshi V; Jindal AK; Mathew B; Rawat A
Genes Dis; 2020 Mar; 7(1):67-74. PubMed ID: 32181277
[TBL] [Abstract][Full Text] [Related]
23. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
24. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.
Sood AK; Francis O; Schworer SA; Johnson SM; Smith BD; Googe PB; Wu EY
Front Pediatr; 2023; 11():1179788. PubMed ID: 37274825
[TBL] [Abstract][Full Text] [Related]
25. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
26. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma.
Durandy A; Kracker S
Blood; 2020 Feb; 135(9):638-643. PubMed ID: 31942637
[TBL] [Abstract][Full Text] [Related]
27. Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Bloomfield M; Klocperk A; Zachova R; Milota T; Kanderova V; Sediva A
Front Pediatr; 2021; 9():697706. PubMed ID: 34350147
[TBL] [Abstract][Full Text] [Related]
28. Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
Thouenon R; Moreno-Corona N; Poggi L; Durandy A; Kracker S
Front Pediatr; 2021; 9():652405. PubMed ID: 34249806
[TBL] [Abstract][Full Text] [Related]
29. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
[TBL] [Abstract][Full Text] [Related]
30. Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients.
Tessarin G; Rossi S; Baronio M; Gazzurelli L; Colpani M; Benvenuto A; Zunica F; Cardinale F; Martire B; Brescia L; Costagliola G; Luti L; Casazza G; Menconi MC; Saettini F; Palumbo L; Girelli MF; Badolato R; Lanzi G; Chiarini M; Moratto D; Meini A; Giliani S; Bondioni MP; Plebani A; Lougaris V
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33080915
[TBL] [Abstract][Full Text] [Related]
31. Activated PI3K
Yin J; Ma J; Xia J; Cao Y; Li C
Front Pediatr; 2022; 10():1077324. PubMed ID: 36605759
[TBL] [Abstract][Full Text] [Related]
32. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.
Moriya K; Mitsui-Sekinaka K; Sekinaka Y; Endo A; Kanegane H; Morio T; Imai K; Nonoyama S
Immunol Med; 2023 Dec; 46(4):153-157. PubMed ID: 37178059
[TBL] [Abstract][Full Text] [Related]
33. Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.
Vanselow S; Wahn V; Schuetz C
Front Immunol; 2023; 14():1208567. PubMed ID: 37600808
[TBL] [Abstract][Full Text] [Related]
34. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
[TBL] [Abstract][Full Text] [Related]
35. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
Cohen JI
Front Immunol; 2018; 9():237. PubMed ID: 29599765
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.
Pham MN; Cunningham-Rundles C
Front Pediatr; 2018; 6():402. PubMed ID: 30619796
[TBL] [Abstract][Full Text] [Related]
37. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus.
Wang Y; Yang Q; Chen X; Tang W; Zhou L; Chen Z; An Y; Zhang Z; Tang X; Zhao X
Genes Dis; 2021 Nov; 8(6):907-917. PubMed ID: 34522717
[TBL] [Abstract][Full Text] [Related]
39. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
Berglund LJ
J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
